BioSig Technologies, Inc.
  • Home
  • About BioSig
    • Overview
    • Leadership
    • Partnerships
  • PURE EP
    • Our Solution
    • Publications
    • Physician Insights
  • Join Our Team
  • News & Media
    • Overview
    • Press Releases
    • BioSig in the News
    • Presentations
    • Events
    • Newsletter
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • BioSig in the News
  • Presentations
  • Events
  • Newsletter

Press Releases

BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19

April 24, 2020

BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19

April 24, 2020

Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

April 21, 2020

BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials

April 21, 2020

BioSig Issues April 2020 Shareholder Update Letter

April 17, 2020

Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax™

April 16, 2020

Positive Data Generated by BioSig Subsidiary ViralClear on COVID-19 Coronavirus Published in bioRxiv

April 9, 2020

BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19

April 3, 2020

Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.

March 31, 2020

BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture

March 25, 2020
  • Previous
    • 1...
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • ...32
    Next
    Award
    BioSig Technologies, Inc.
    Sign Up for BioSig Updates Contact Us
    Twitter linkedin Facebook
    © 2023 BioSig Technologies, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap